Reply to: Is the role of eosinophils in refractory chronic cough truly dismissed? Mepolizumab reduced blood and sputum eosinophils, but not eosinophil-derived neurotoxin
<title>Extract</title> <italic>Reply to W. Zhan and co-workers:</italic> The recently published MUCOSA trial in the <italic>European Respiratory Journal</italic>, which evaluated the effects of mepolizumab on objective cough frequency in patients with refractory chronic cough (RCC), has prompted a re-evaluation of the role of eosinophils in cough pathophysiology [1].
Authors
- Catie Obminski
- Roma Sehmi (ORCID: https://orcid.org/0000-0003-0968-6304)
- Sue Beaudin
- Elena Kum (ORCID: https://orcid.org/0000-0002-6548-2632)
- Lesley Wiltshire
- K Howie
- K Killian
- J Wattie
- Mustafaa Wahab
- Jaclyn A. Smith
- Wafa Hassan (ORCID: https://orcid.org/0000-0002-1461-4367)
- Gail M. Gauvreau (ORCID: https://orcid.org/0000-0002-6187-2385)
- Paul M. O'Byrne (ORCID: https://orcid.org/0000-0003-0979-281X)
- Nermin Diab
- Christiane Whetstone
- Imran Satia (ORCID: https://orcid.org/0000-0003-4206-6000)
- Kimberley Holt (ORCID: https://orcid.org/0000-0003-0413-8085)
- Danica Brister
Institutions
- University of Calgary (CA)
- McGill University Health Centre (CA)
- University of Manchester (GB)
- McGill University (CA)
- St. Joseph’s Healthcare Hamilton (CA)
- McMaster University (CA)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2026-05-01
- DOI
- https://doi.org/10.1183/13993003.00143-2026
- Primary Topic
- Respiratory and Cough-Related Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- GlaxoSmithKline